Comparative Pharmacology
Head-to-head clinical analysis: LUPRON versus ZOLADEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LUPRON versus ZOLADEX.
LUPRON vs ZOLADEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gonadotropin-releasing hormone (GnRH) agonist. Chronic administration suppresses pituitary gonadotropin secretion, leading to decreased testosterone and estradiol levels.
Gonadotropin-releasing hormone (GnRH) agonist; initially stimulates and then suppresses luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release, leading to reduced sex steroid production.
3.75 mg intramuscularly once monthly or 11.25 mg intramuscularly once every 3 months. For endometriosis, 3.75 mg intramuscularly monthly for up to 6 months. For central precocious puberty, 0.3 mg/kg intramuscularly every 28 days.
3.6 mg subcutaneously every 28 days (prostate cancer, endometriosis) or 10.8 mg subcutaneously every 12 weeks (prostate cancer).
None Documented
None Documented
Terminal half-life approximately 3 hours after subcutaneous administration; in patients with renal impairment, half-life may be prolonged
Approximately 4.2 hours (subcutaneous); due to continuous release from depot formulation, effective half-life is extended to ~28 days.
Renal (primarily as metabolites), <5% unchanged; fecal ~5%
Primarily renal (approximately 20% as unchanged drug); remainder as metabolites via biliary/fecal (approximately 80%).
Category C
Category C
GnRH Agonist
GnRH Agonist